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Abstract 
 
Objective: This Master’s paper aims to characterize the extent of HPV vaccination in the United 
States, and to summarize the current literature about HPV vaccination, series completion, and 
factors related to uptake and completion. It also aims to determine the percentage of HPV 
vaccine completion and on-time dosing, as well as identify factors associated with series 
completion and on-time dosing. 
 
Design: We determined the rates of HPV vaccination and series completion through a systematic 
review. We also conducted a secondary data analysis of the North Carolina Immunization 
Registry (NCIR) to answer a focused clinical question about the rates of HPV vaccination 
completion and on-time dosing among a select population of females aged 9-26 years of age with 
at least one dose of the HPV vaccine. 
 
Results: The literature review indicated that the rates of HPV vaccination vary widely depending 
on the type of patient population selected. Initiation rates varied between 5 – 77% and 
completion rates between 0.2% and 58.2%. Correlates for uptake and series completion varied 
for each study, but most found associations between race, ethnicity, insurance status and the 
measured outcomes. Of the 138,823 females analyzed in the secondary data analysis, 55% 
completed the vaccine series and 28% completed the series on-time. The percentage of those 
receiving the vaccine on-time has decreased each year from 43% in 2006 to 25% in 2009. 
African American race and public funding were significantly associated with lower rates of on-
time dosing as well as series completion when compared to White race and private funding, 
respectively.  
 
Conclusions: Although many studies in the literature were limited by flaws in study design or by 
small sample sizes, the review identified health disparities related to socioeconomic and racial 
disparities. The review also highlighted the fact that the HPV vaccination rate for both initiation 
and completion is relatively low when compared to other recommended vaccines. The secondary 
data analysis corroborated these findings. Among girls and young women who initiate the HPV 
vaccination series, overall completion rates are low, but given enough time (three years), most of those 
who begin the series will complete it. On-time dosing rates, however, are declining, and have been 
hovering at 25% for the past two years. The significance of delayed dosing with respect to vaccine 
immunogenicity and vaccine effectiveness are not well defined. Strategies to enhance both on-time 
receipt of HPV vaccine and series completion should be broadly encouraged.   
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Introduction 
The human papillomavirus (HPV) infects an estimated 6.2 million people in the United 
States every year, and is the most common sexually transmitted infection.
1
 Persistent infection 
with high-risk HPV serotypes, particularly types 16 and 18, is the most important risk factor for 
developing cervical cancer
1
 while infection with  HPV types 6 and 11 is responsible for most 
genital wart cases.
1
 The quadrivalent HPV vaccine (Gardasil®) is designed to prevent anogenital 
disease and cervical cancer associated with HPV types 6, 11, 16, and 18.
2
 Since HPV is such a 
common sexually transmitted infection, the HPV vaccine is most effective when administered 
prior to sexual debut.
3
 For this reason the Advisory Committee on Immunization Practices 
(ACIP) recommended to routinely vaccinate females 11-12 years of age in 2007.
1
  Catch-up 
vaccination of women not previously vaccinated extends up through 26 years of age. The 
American Academy of Pediatrics and the American Academy of Family Practitioners also 
espouse similar recommendations.
4
 In October of 2009, the ACIP updated its recommendations 
about HPV vaccination.
5-6
 The bivalent vaccine was also approved for use in females 9-26 years 
of age,
5
 and the quadrivalent vaccine was approved for use in males 9-26 years of age in order to 
prevent anogenital warts.
6
 Nevertheless, the focus of this report is on the use of the vaccine in 
women, specifically the quadrivalent product, given the relatively recent introduction of the 
bivalent vaccine and use of the quadrivalent vaccine in males.  
Despite the federal government’s approval of the vaccine, its recommendation to vaccinate 
females from 9-26 years of age,
1
 and its addition of Gardasil® to the Vaccines for Children 
Program,
7
 the reported rates of HPV vaccination for young girls remains low. Nationally, only 
37.2% of adolescent females (aged 13-17) had initiated the HPV vaccine series in 2008, and only 
17.9% of females had received all 3 doses.
8
 The clinical trials demonstrating the effectiveness of 
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the vaccine against cervical cancer and genital warts had high rates of compliance,
9
 and thus the 
effectiveness of the vaccine in girls who do not complete the series is unknown.   
The quadrivalent vaccine is recommended to be administered as 3 separate doses with the 2
nd
 
and 3
rd
 dose given at 2 and 6 months following the first dose, respectively. In clinical practice, it 
is likely that some females will receive their 2
nd
 and 3
rd
 vaccine doses at intervals outside the 
recommended dosing window.
10-12
 Currently, the standard of care is to finish the three-doses 
regardless of the schedule.
1
 There are limited data to assess how the late timing of the intervals 
between the 1
st
 and 2
nd
 or 2
nd
 and 3
rd
 dose of the vaccine will affect the humoral immune 
response, but studies are currently underway.
13-16
   
To our knowledge, no systematic reviews about the uptake, completion, and adherence to 
dosing schedules of the HPV vaccine exist in the literature. Few studies have examined 
correlates for completion of the HPV vaccination series.
17-19
 However, we are aware of no study 
documenting factors associated with on-time dosing in addition to vaccine series completion. 
This report is a new systematic review of the current state of the literature on the subject. The 
review focuses on the completion rates of the HPV vaccine and on factors that are associated 
with series uptake or completion. The goal of this review is to highlight the extent to which the 
HPV vaccine is being completed when initiated, along with the factors associated with 
completion and uptake. This information will give insight into ways physicians, public health 
professionals, and policymakers can act in order to address the problems of low uptake and poor 
completion rates. Low uptake may reduce vaccine’s impact on the population to prevent cervical 
cancer, while poor completion rates may reduce the effectiveness of the vaccine against cervical 
cancer and anogenital disease.   
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In order to answer the question about actual uptake and completion of the HPV vaccine, we 
sought observational studies characterizing HPV vaccination rates (uptake or completion) and 
factors associated with vaccination in women between the ages of 9-26. Clinical trials were not 
chosen in this review due to the fact that trial settings have inflated adherence rates, and the goals 
of this review were to determine actual HPV vaccination rates in various real-world practice 
settings, as well as to determine socioeconomic and other demographic factors associated with 
these rates.  
Methods 
Eligibility Criteria:  
Studies which included women living in the United States who were also between the ages of 
9-26 (or any group within that range) were eligible for review. All observational study designs 
(cross-sectional, retrospective cohort, and prospective cohort) were eligible. Given the paucity of 
data, since the vaccine is relatively new, information from published abstracts without a 
corresponding published manuscript were also included. All controlled trials (randomized and 
non-randomized) that measured the effectiveness of an intervention program were excluded from 
the review in order to assess the completion rates of the HPV vaccination in a real-world clinical 
setting rather than in an experimental situation. Included studies had to have the primary 
outcome as the rate of vaccine uptake or vaccine completion. Studies examining socioeconomic 
and demographic factors associated with vaccine utilization were also included. Studies 
examining factors for vaccination acceptance (intention to receive the vaccine or openness to 
receiving the vaccine) were excluded from analysis due to the fact that acceptance and actual 
vaccine uptake are different outcomes that have different factors associated with them. Studies 
were limited to English speaking articles from 2006 until March 2010. This date range includes 
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all studies since the FDA approval of the HPV quadrivalent vaccine, which was necessary for 
widespread dissemination and acceptance of the vaccine.  
Information Sources: 
We conducted literature searches using PubMed (2006-present) and Google Scholar (2006 – 
present). Limits on both databases were set to English language articles published after 2006. 
The last search was run on March 8, 2010. In addition to database searching, studies were 
identified through the cross-checking of reference lists of the selected articles. 
Search Strategy:  
Search terms included the following MeSH terms in PubMed: Papillomavirus vaccines, 
vaccination statistics and numerical data, vaccination administration and dosage, vaccination 
trends, vaccination utilization, and immunization schedule. The following keywords were also 
used in both PubMed and Google Scholar: HPV vaccination rates, HPV vaccination uptake, 
delayed dosing vaccine, completion rates, timeliness, and completion. 
The search strategy conducted using PubMed is shown below:  
1. Papillomavirus Vaccines[Mesh] AND ("Vaccination/statistics and numerical data"[Mesh] 
OR "Vaccination/trends"[Mesh]) 
2. Papillomavirus Vaccines[Mesh] AND ("Vaccination/administration and dosage"[Mesh] 
OR "Vaccination/utilization"[Mesh]) 
3. Immunization Schedule[Mesh] AND "Papillomavirus Vaccines"[Mesh] 
4. Papillomavirus Vaccines[Mesh] AND completion 
5. HPV vaccination rates 
6. HPV vaccination uptake 
7. delayed dosing vaccine 
8.  ("Vaccination/administration and dosage"[Mesh] OR "Vaccination/statistics and 
numerical data"[Mesh] OR "Vaccination/trends"[Mesh] OR 
"Vaccination/utilization"[Mesh]) delayed 
9. Immunization Schedule[Mesh] AND uptake 
10. Immunization Schedule[Mesh] AND completion rates 
11. Immunization Schedule[Mesh] AND timeliness 
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Study Selection:  
After the database searches, studies were screened based on relevant titles by the author 
(WT) in an unblinded manner. Eligible studies were then identified using abstracts to further 
narrow the selection to articles relevant to HPV vaccine uptake, series completion, and factors 
associated with both uptake and completion. Studies were excluded if they were not written in 
English, were clinical trials, or had a study population not based in the United States. The 
remaining articles were then fully reviewed by the author (WT).  
Each stage of the study selection (screening, eligibility criteria, and full text review) was 
conducted by one author (WT) in an unblinded fashion. If the author had any concerns regarding 
the eligibility or relevancy of a study, he discussed the study with an expert methodologist (AV) 
and physician (EBW) who is an expert in the field of vaccines.   
Data Collection: 
The data from each study included in the full-text review were extracted using a standardized 
form based on a critical appraisal form that has been pilot tested and used in a graduate-level 
literature appraisal course at the UNC Gillings School of Global Public Health. I extracted the 
information from all the studies included in the full-text review.  
The information extracted from each trial included: author, title, study year, study 
design/type, length of follow-up, source population, main results, study strengths, study 
weaknesses (biases), generalizability, conclusion, and overall study quality.  
Data Quality:  
When assessing risk of bias in individual studies, the author examined the risk of selection 
bias (patient selection, inclusion/exclusion criteria, loss to follow-up, dropouts), measurement 
bias (equal measurement methods, valid data collection methods, reliable tools), and 
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confounding bias (statistical adjustments) in order to determine the quality and reliability of each 
study’s results. Outcome level biases were not assessed given the paucity of data and 
heterogeneity between study populations and outcome measures.  
The quality of each fully reviewed article was evaluated using an appraisal scheme based on 
USPSTF guidelines. Each article was graded based on its strength of study design, risk of bias, 
implementation, and generalizability of results. The article was then assigned a grade of poor, 
fair, or good. Since there are so few studies examining the completion rates of HPV vaccination 
and factors associated with uptake or series completion, poor quality studies were included in the 
review. 
When reporting outcomes measures, the studies investigating vaccine uptake and series 
completion summarized rates in terms of percentages. The factors associated with uptake and 
completion were reported using either odds ratios or adjusted risk ratios.  
The potential for publication bias or selective reporting is low as these are observational 
studies with results that would be informative regardless of the findings. Selective reporting of 
data might be a problem, but the methods and results were reviewed for each study to detect any 
discrepancy between stated design and reporting of the actual outcomes.  
Results 
Study Selection: 
A total of 14 studies were identified for inclusion in the review (Figure). The initial literature 
search yielded 530 article citations. Based on the title alone, 390 articles were excluded as 
irrelevant. After reviewing the abstracts and excluding studies based on previously described 
criteria, such as experimental trials and studies about vaccine acceptability, 12 articles were 
identified for a full review. An additional two articles that fit eligibility criteria were identified 
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by checking references of the 12 articles identified through the literature search. Of the 14 total 
studies included in the systematic review, one was an abstract that had no corresponding 
published full manuscript. 
Flow Diagram about Search Strategy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Literature Search:  
Databases: PubMed and Google Scholar 
Limits: English-language, 2006-present 
Search results combined (n = 530) 
Articles screened on basis of Title 
Included (n = 140) 
Excluded (n=390) 
Irrelevant title: 390 
Review of Abstracts 
Included (n = 12) 
Excluded (n = 138) 
Irrelevant to topic:  109 
Vaccine Acceptance: 17 
Not about HPV Vaccine: 7 
Clinical Trial setting: 2 
Not in the US: 3 
 
Review of References 
Included (n = 2)  
Full text Review (n = 14) 
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Study Characteristics:  
The 14 studies were all observational reports published in English within the past four years. 
All the studies were based in the United States. Three of the studies
17, 20-21
 were prospective 
cohort in design, three were retrospective cohort studies,
18-19, 22
 and eight were cross-sectional 
studies.
23-30
 The prospective and retrospective cohort studies had follow-up periods ranging from 
6 to 24 months with 5 out of 6 of these studies having follow-up periods lasting at least 12 
months.
17-20, 22
 The cross-sectional studies sampled their respective study populations between 
October of 2006 and November of 2008, and four studies sampled between May and October of 
2007.
23-25, 27
 The study populations for all 14 studies varied greatly; for example, some studies 
sampled from a large, managed care organization like Kaiser Permanente while another study 
used a small set of urban pediatric practices affiliated with one academic institution. 
The cohort studies (both retrospective and prospective) enrolled females between the ages of 
9 and 26 years,
17, 20
 but some studies focused more on adolescents (9-18 years old)
19, 22
 while 
others focused on young women (13-26 years old).
21
 These studies obtained their study 
population from a large managed care organization (Kaiser Permanente),
17, 20, 22
 an urban 
hospital-based teen health center,
21
 and university-based outpatient clinics.
18-19
 The cross-
sectional studies surveyed females between the ages of 11 and 26 years of age,
24-27, 29-30
 as well 
as parents of females aged 9 to 18 years.
23, 28
 Four studies used a nationally representative sample 
for their surveys,
23-24, 29-30
 while four studies surveyed females from a specific area, such as two 
universities
26
 or five urban pediatric practices.
27
  
Depending on the study in question, the outcomes addressed were either HPV vaccine 
initiation rates, HPV vaccine completion rates, or both. Three of the 14 articles concentrated on 
initiation rates of the HPV vaccine,
20, 24, 27
 two focused on completion rates,
17-18
 and six 
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addressed both.
19, 21-22, 25-26, 30
 The other three articles did not explicitly look at initiation or 
completion rates, but only at factors associated with vaccine uptake or series completion.
23, 28-29
 
Factors associated with either vaccine initiation or completion were discussed in all cohort 
studies
17-22
 and in five of the eight cross-sectional studies.
24, 26, 28-30
 One cross-sectional study 
discussed factors associated with acceptance of a hypothetical 3-shot vaccine,
23
 another 
discussed factors associated with intent to vaccinate,
25
 while a third study did not discuss the 
subject.
27
 Please refer to Table 1 for a comprehensive review of the study characteristics. 
Table 1. Study Characteristics 
Author Title Year Design Study Duration 
Source 
Population 
Age 
Range 
Chao, et al 
(1) 
Correlates for completion of 
3-dose regimen of HPV 
vaccine in female members 
of a managed care 
organization 
2009 
Prospective 
Cohort 
Selected women 
from 10/06 to 
3/07, who 
maintained 
membership for at 
least 12 months. 1 
Year post 
Initiation, but 
post-hoc analysis 
up to 2 years post 
initiation 
Kaiser 
Permanente 
Southern 
California 
9 to 26 
Chao, et al 
(2) 
Correlates for Human 
Papillomavirus Vaccination 
of Adolescent Girls and 
Young Women in a 
Managed Care Organization 
2010 
Prospective 
Cohort 
18 months 
Kaiser 
Permanente 
Southern 
California 
9 to 26 
Chao, et al 
(3) 
Papanicolaou Screening 
Behavior in Mothers and 
Human Papillomavirus 
Vaccine Uptake in 
Adolescent Girls 
2009 
Retrospective 
Cohort 
12 months for 
initiation, 18 
months for 
completion 
Kaiser 
Permanente 
Southern 
California 
9 to 17 
Conroy, et 
al 
Human Papillomavirus 
Vaccine Uptake, Predictors 
of Vaccination, and Self-
Reported Barriers to 
Vaccination 
2009 
Prospective 
Cohort 
6 months 
Urban, 
hospital-based 
teen health 
center 
(location 
unspecified) 
13 to 26 
13 
 
Dempsey, 
et al (1) 
Patient and Clinic Factors 
associated with adolescent 
human papillomavirus 
vaccine utilization within a 
university-based health 
system 
2010 
Retrospective 
Cohort 
14 months 
University of 
Michigan 
Health System 
outpatient 
clinics for peds, 
FM, and 
ob/gyn 
9 to 18 
Dempsey, 
et al (2) 
Parents' Views of 3 Shot-
Related Visits: Implications 
for Use of Adolescent 
Vaccines Like Human 
Papillomavirus Vaccine 
2009 
Cross-
Sectional 
Survey 
Cross sectional, 
7/07 - 8/07 
Random 
sample of 2906 
adults from 
Knowledge-
Panel (US 
adults) 
Parents 
of 9 to 17 
year olds 
Jain, et al 
Human papillomavirus (HPV) 
awareness and vaccination 
initiation among women in 
the United States, National 
Immunization Survey - Adult 
2007 
2009 
Cross-
Sectional 
Survey 
Cross sectional, 
5/07 - 8/07 
National 
Immunization 
Survey - Adult 
(telephone 
survey, 7055 
respondents) 
18 to 26 
Kahn, et al 
Rates of Human 
Papillomavirus Vaccination, 
Attitudes about Vaccination, 
and Human Papillomavirus 
Prevalence in Young Women 
2008 
Cross-
Sectional 
Survey 
Cross-sectional, 
10/06 to 5/07 
Hospital-based 
teen health 
center, ob/gyn 
clinic, and std 
clinic in 
Cincinnati 
13 to 26 
Licht, et al 
Is use of the HPV vaccine 
among female college 
students related to HPV 
knowledge and risk 
perception? 
2009 
Cross-
Sectional 
Survey 
Cross-sectional, 
unknown date 
Two 
universities 
(location 
unspecified) 
18 to 26 
Neubrand, 
et al 
Factors Associated with 
Completion of the Human 
Papillomavirus Vaccine 
Series 
2009 
Retrospective 
Cohort 
17 - 23 months 
follow-up 
University-
based pediatric 
clinic or 
community 
practice 
(location 
unspecified) 
Under 21 
Patel, et al. 
Are Our Adolescent Females 
Becoming "One Less"? HPV 
Vaccination Rates and 
Barriers to Vaccination 
2009 
Cross-
Sectional 
Chart Review 
7/07 - 10/07 
Five Urban 
Pediatric 
Practices 
affiliated with 
an academic 
institution in 
New York City 
11 to 21 
Reiter, et 
al 
How much will it hurt? HPV 
vaccine side effects and 
influence on completion of 
2009 
Cross-
sectional 
survey 
10/08 - 11/08 
Five North 
Carolina 
counties 
Parents 
of 10 to 
18 year 
14 
 
 
Outcome Results of Individual Studies: 
The results of each individual study are shown in the table below.  
Table 2. Results of Individual Studies 
Author 
Initiation 
Rates 
Completion Rates Factors Associated with Initiation or Completion 
Chao, et al 
(1) 
n/a 
Overall: 42.8% 
(12,663 / 29,598) 
 
9-17 year olds: 
41.9% (10,347 / 
24,676) 
 
18-26 year olds: 
47.1% (2,316 / 
4,922) 
 
With 2 years of 
follow-up, overall 
completion rate 
increased to 50% 
For 9-17 year olds: 
Older age: 17 year olds versus 11-12 year olds 
RR: 0.87 (0.82-0.93) 
Black Race versus White: 
RR: 0.7 (0.64-0.77) 
Hispanics versus Whites: 
RR: 0.88 (0.83-0.93) 
Medi-cal coverage versus none: 
RR: 1.14 (1.07-1.22) 
Neighborhood education level (RR for a 10% in 
percentage of adults with high school diploma in census 
block) 
RR: 1.03  (1.02-1.05) 
 
For 18-26 year olds: 
 
Same as younger group, but not statistically significant, 
except for provider type. 
 
Family medicine versus pediatrics: 
RR: 1.24 (1.08-1.42) 
 
Internal medicine versus pediatrics: 
RR: 1.26 (1.06-1.50) 
the three-dose regimen olds 
Rosenthal, 
et al 
Predictors of HPV vaccine 
uptake among women aged 
19-26: Importance of a 
physician's recommendation 
2010 
Case-control 
survey 
1/07 - 4/07, 18 
months follow-up 
Large US 
managed care 
plan affiliated 
with i3 Innovus 
19 to 26 
Stokley, et 
al 
National, State, and Local 
Area Vaccination Coverage 
Among Adolescents Aged 13 
- 17 Years -- United States, 
2008 
2009 
Cross-
Sectional 
Survey 
All of 2008 
National 
Immunization 
Survey - Teen 
13 to 17 
15 
 
Chao, et al 
(2) 
Overall: 29.4% 
(83,904 / 
285,265) 
 
9-17 year olds: 
37% (67,297 / 
179,580) 
 
18-26 year 
olds: 16% 
(16,607 / 105, 
685) 
n/a 
For  9-17 year olds: 
Older age: 15-16 year olds in reference to 11-12 year olds 
RR: 1.14 (1.12 – 1.16) 
13-14 year olds in reference to 11-12 year olds: 
RR: 1.17 (1.15 – 1.18) 
 
Black Race in reference to Whites: 
RR: 0.93 (0.90 – 0.95) 
 
Higher income (RR is regarding every $10,000 increase) 
RR: 1.02 (1.01 – 1.02). 
 
Male PCP versus female: 
RR: 0.92 (0.91 – 0.93) 
 
For 18-26 year olds: 
 
Older age: 25-26 year olds in reference to 18 year olds 
RR: 0.31 (0.29 – 0.33) 
 
Black Race in reference to Whites 
RR: 0.82 (0.77 – 0.88) 
 
Hispanics versus Whites 
RR: 0.95 (0.91 – 0.99) 
 
Chao, et al 
(3) 
Overall: 27% 
(40,288 / 
108,062) 
Overall: 42% 
(7,713 / 18,275) 
 
41% (7,430 / 
18,275) 
completed series 
within 1 year of 
initiation and 
were within the 
recommended 
dosing schedule, 
while 
1.5% (283 / 
18,275) 
completed the 
series, but were 
not on-time. 
Factors for initiation: 
If mother had history of Pap test: OR 1.47 (1.43 – 1.52) 
If mother had abnormal Pap test: 
OR: 1.11 (1.07 – 1.14) 
If mother had genital warts: 
OR: 1.19 (1.10 – 1.28) 
If mother had other STIs: 
OR: 1.13 (1.04 – 1.22) 
 
Factors for Completion: 
If mother had at least 1 Pap test in the past 3 years: 
OR 1.42 (1.31 – 1.54) 
If mother had abnormal Pap test: 
OR: 1.16 (1.07 – 1.24) 
If mother had genital warts: 
OR: 1.26 (1.05 – 1.52) 
 
History of STI inversely associated with completion in 
African Americans but positively associated with 
completion in Asians. 
OR: 0.67 (0.43 – 1.04) and 4.92 (1 – 24.25), respectively 
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Conroy, et 
al 
Overall: 36% 
(68 / 189) 
Overall: 13% 
(9 / 68) 
 
14.7% (10 / 68) 
initiated late 
enough so they 
weren’t due for a 
second dose by 
the end of the 
study, which 
raises completion 
rate to 16% (9 / 
58) 
 
45% (26 / 58) 
were late for 2nd 
dose. 
Factors associated with Initiation: 
Age, in years: 
OR: 0.64 (0.52 – 0.77), unadjusted 
Insurance coverage for versus none: 
OR: 5.31 (1.61 – 17.49) 
Normative beliefs (scale of 1-5 about how a patient 
perceives importance of the vaccine): 
OR: 2.21 (1.29 – 3.79) 
Dempsey, 
et al 
Overall: 28% 
(2,855 / 
10,082) 
 
78% (2,038 / 
2,625) 
received a 
second dose 
Overall: 40% 
(1,134 / 2,855) 
 
75% (1,134 / 
1,515) completed 
series after 
receiving 2nd 
dose. 
 
28% (318 / 1,134) 
completed series 
on-time. 
 
69% (782 / 1,134) 
completed series 
within 1 year. 
 
15% (706 / 4,712) 
completed series 
among a sub-
population of girls 
who had >12 
months from first 
visit to study end 
date (Overall 
completion rate, 
not rate within 
group that 
initiated). 
Factors associated with initiation: 
 
Black race versus White race: 
OR: 1.06 (0.91 – 1.24) 
 
Older age, 16+ years old versus 11-12 year olds: 
OR: 1.92 (1.66 – 2.23) 
 
Private Insurance versus Public Insurance: 
OR: 0.52 (0.45 – 0.59) 
 
Preventive visits versus problem-focused visits: 
OR: 5.18 (4.64 – 5.79) 
 
Factors associated with completion: 
African-American race and public health insurance 
associated with lower completion rates (absolute number 
results not shown). 
Dempsey, n/a n/a Factors associated with NOT vaccinating (barriers): 
17 
 
et al N= 1025, percentages don’t add up to 100 because 
parents could choose more than 1 barrier. 
 
Unnecessary for healthy adolescents to be seen so 
frequently: 15% (12 – 17%) 
Adolescent would miss too much school: 14% (11 – 17%) 
Problems getting off work: 11% (8 – 14%) 
Too much time: 10% (7 – 13%) 
Adolescent doesn’t like shots: 9% (6 – 11%) 
Against child receiving shots: 7% (5 – 9%) 
No regular health care provider: 2% (1 – 3%) 
Transportation problems: 2% (1 – 4%) 
 
Jain, et al 
Overall: 10% 
(17 / 168) 
n/a 
Univariate Factors associated with initiation: 
 
Not being married: 11.8% (5.7 – 22.7%) 
>200% FPL: 22.8% (11.2 – 40.7%) 
Receiving Hep B vaccine: 14.5% (7.2 – 27.2%) 
Having Insurance: 12.5% (6.1 – 24.1%) 
Results of analysis of factors associated with HPV vaccine 
initiation not presented due to lack of reliability caused 
by small sample sizes. 
Kahn, et al 
Overall: 5% (4 
– 7%) 
Overall 0.2% (0 – 
0.6%) (measuring 
out of all subjects, 
not just those 
who initiated) 
n/a (measured factors associated with vaccination intent 
and beliefs of vaccination) 
Licht, et al 
Overall: 43.6% 
(177 / 406) 
Overall: 53% (93 / 
177) 
Factors associated with Initiation: 
Age: Students 19-26 years old compared to 18 years old : 
OR: 0.27 (0.17 – 0.41) 
African-American race compared to White race: 
OR: 0.26 (0.08 – 0.81) 
Asians compared to Whites: 
OR: 0.42 (0.18 – 0.99) 
 
HPV knowledge and vaccination status not related, 
except for knowledge that genital warts are caused by 
HPV 
OR: 1.85 (1.20 – 2.93), adjusted 
Neubrand, 
et al 
n/a 
Overall: 58.2% 
(205 / 352) 
 
12% took more 
than 1 year to 
complete series. 
Factors associated with vaccine completion: 
 
Bivariate analysis showed that Caucasians (69.1% 
completed) were more likely to complete the series than 
African Americans (48.6% completed) or Hispanics (38.8% 
completed). 
Private insurance (65.6% completed) also associated with 
completion of the series when compared to those with 
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Medicaid/SCHIP (45.3% completed). 
 
Logistic Model: 
Hispanics versus Caucasians: 
OR: 0.341 (0.160 – 0.727) 
African-Americans and Caucasians did not differ 
statistically (p = 0.081) 
If second visit was a nonstick visit versus a vaccine-only 
visit: 
OR: 0.164 (0.078 – 0.343) 
No statistical difference between sick visit versus vaccine-
only visit (p = 0.538) 
Patel, et 
al. 
Overall: 67% 
11 – 12 year 
olds: 55% 
18 – 21 year 
olds: 77% 
n/a n/a 
Reiter, et 
al 
n/a n/a 
Factors associated with vaccine initiation: 
 
83% (154/186) had pain from tetanus booster while 62% 
(116/186) had pain from HPV vaccine at time of injection. 
OR: 6.43 (2.88 – 16.90). 
 
70% (133/191) had pain from tetanus booster while 45% 
(85/191) had pain from HPV vaccine in the hours after 
injection. OR: 4.43 (2.45 – 8.57). 
 
Pain from vaccination did not influence timely uptake or 
completion of vaccine. 62% (114/185) of parents of 
daughters who completed series reported pain at time of 
injection while 68% (19/28) of parents with daughters 
who were late for their 2nd or 3rd dose reported pain. OR: 
0.76 (0.33 – 1.77) 
Rosenthal, 
et al 
n/a n/a 
Factors associated with vaccination: 
 
Student status (yes versus no): 
OR: 2.79 (1.53 – 5.09) 
Personal Importance of vaccine (very important versus 
other): 
OR: 7.69 (4.22 – 14.01) 
Physician Discussion (yes versus no): 
OR: 93.5 (39.1 – 223.6). 
 
For people with discussion with a physician, each increase 
of 1 point on the Likert scale was associated with a 41% 
increase OR: 1.41 (1.06 – 1.88) in odds of vaccination. 
Stokley, et Overall: 37.2% Overall (whole Factors associated with initiation: 
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al (6,635 / 
17,835) in 
2008, 
compared with 
25.1% (740 / 
2,947) in 2007. 
sample): 17.9% 
(3,193 / 17,835) 
 
Overall (among 
those who 
initiated): 48.1% 
(3,193 / 6,635) 
 
Bivariate analysis: Hispanics had higher coverage than 
Whites: 44% (896 / 2,017) versus 35% (4,420 / 12,628). 
 
Adolescent females below poverty level had higher 
vaccination initiation coverage for HPV vaccine than 
those at or above poverty level: 45.4% (993/2140) versus 
35.8% (5353/14951), but not 3 dose coverage (data not 
shown). 
 
Factors associated with completion: 
 
Poorer females completed series at a rate of 14.9% (319 / 
2,140) while richer females completed at a rate of 18.6% 
(2,781 / 14,951). 
 
Completion rates were 19.5% (2,463 / 12,628), 14.9% 
(288/1,934), and 14.7% (297 / 2,017) for Whites, Blacks, 
and Hispanics, respectively. 
 
Synthesis of Results:  
The study designs, participants, reported outcomes, and measured factors associated with the 
outcomes varied markedly for all of the 14 studies in this review, and therefore results are 
synthesized qualitatively rather than through a meta-analysis.  
The results of the review show a wide range of initiation rates for the HPV vaccine varied 
between 5% and 77% (9 studies), with the majority of studies falling between 25% and 45% (6 
studies). The completion rates of the vaccine varied between 0.2% and 58.2% (8 studies), with 
the majority of studies falling between 40% and 50% (4 studies). Three studies reported on-time 
dosing, but did not further describe factors associated with the finding. There was wide 
variability in the results, as demonstrated by the range of 1.5% to 72% for women receiving the 
vaccine in a delayed fashion. 
In terms of factors associated with uptake, the studies varied in which correlates they decided 
to choose, the statistical methods in which they analyzed these factors, and also in the 
populations in which these correlates applied. Therefore, while it is difficult to combine the 
20 
 
results, a few trends emerged. In the younger age group (under 18 years old), older age is 
associated with increased initiation. On the other hand, young women aged 18-26 years are more 
likely to initiate the vaccine if they are younger, which implies that vaccination initiation rates 
are highest in the late adolescent age group. Those who are too young (9-11 years old) or too old 
(24-26 years old) have not initiated HPV vaccination as much as the 14-18 year olds. A few 
studies also documented a racial/ethnic disparity where Whites had a higher rate of initiation 
than other races and ethnicities. Some studies, however, showed that Blacks were more likely to 
initiate the vaccine than Whites. One interesting study by Chao, et al.
22
 showed that mothers who 
received a recent pap smear or who had a history of warts, abnormal pap test, or other STI were 
more likely to have daughters who started the HPV vaccine. An association with insurance status 
is also unclear – one study reported that having insurance compared to no insurance is predictive 
of vaccination initiation, but another found that public insurance was better than private in terms 
of initiation rates.  
In terms of factors associated with completion, the results were also difficult to synthesize 
given the same reasons highlighted above for the factors associated with vaccine initiation. 
Nevertheless, there are still a few trends of note. One is that people with private insurance more 
likely to complete the series than those with public insurance. Economically disadvantaged 
females also completed the series at a lower rate than those at or above the poverty level. The 
racial and ethnic disparities also exist, where Whites are more likely to complete the vaccine 
series than African Americans or Hispanics. The study by Chao, et al. investigating mother-
daughter pairs also showed similar results to the initiation arm, except that African American 
mothers with a history of STI had daughters that were less likely to complete the series, but 
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Asian mothers with a history of STI had daughters that were much more likely to complete the 
series.
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Study Quality: 
The cross-sectional studies have the greatest potential for confounding and temporal effects. 
Many of the studies suffered from small sample sizes, large chunks of missing data, and poor 
generalizability. A summary of the major potential sources of bias in each study are shown in 
Table 3. 
Table 3. Risk of Bias within Studies 
Author Possible sources of Bias 
Chao, et al (1) 
Cannot capture all results outside of electronic system, had 40-60% missing data 
for race/ethnicity (no mention of sample size in Logistic model) 
Chao, et al (2) 
A lot of missing data for race/ethnicity (50%). No mention of sample size in 
Logistic Model 
Chao, et al (3) 
A lot of exclusions limit generalizability, used census data to indicate SES. Also 
used pap test history as a surrogate for mom's view on vaccination, which is not 
an accurate representation of vaccine attitudes. No mention of sample size in 
logistic model 
Conroy, et al 
Small sample, limited generalizability (hospital setting), short interval between 
recruitment and study. 
Dempsey, et al (1) 
Small sample with respect to completion, limited generalizability (university 
health system), no women over age 18, no subjects without insurance. 
Dempsey, et al (2) 
Hard to generalize, used a hypothetical vaccine scenario. Survey had fixed 
responses which could bias answers. Response bias. 
Jain, et al 
Small sample (only 168 women), no females younger than 18 years old, a cross-
sectional design, subject to recall bias and non-response bias. Administered soon 
after approval, early in the process. 
Kahn, et al 
Small sample, subject to selection bias and also did not have vaccine availability 
in clinics. No absolute numbers reported, only percentages. 
Licht, et al 
Small sample, used convenience sample, so subject to selection bias. Weak study 
design. No way to validate survey answers. Not generalizable, no age under 18. 
Neubrand, et al 
Small sample, limited generalizability (only 1 academic center). Cannot capture 
vaccinations outside clinic. Did not report sample used for logistic regression. 
Patel, et al. 
Poor information, not enough detail about the study. No absolute numbers 
given, no definition of vaccination rate. 
Reiter, et al Recall bias, parental opinion rather than vaccinee's. Small sample size. 
Rosenthal, et al 
Landline telephone survey, risk of sampling bias. Underestimate of vaccination 
coverage due to incomplete records. Insufficient sample size for subgroup 
analysis. 
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Stokley, et al 
Only 19-26 year olds. Low response rate for surveys. Did not say how they 
randomized. Missing data/exclusions. Recall bias possible. Difficult to generalize 
 
The table below summarizes each study’s quality. Each study was evaluated based on an 
appraisal scheme outlined in the methods. Many studies had poor generalizability given a limited 
sample population and age restriction. The cohort studies were either fair or good quality, but 
most of the cohort studies were limited to one study site or location,
19
 and two of these studies 
were further limited by a small sample size.
18, 21
 The exceptions, however, were three studies by 
Chao that included many patients captured from a data repository within a managed care 
organization in southern California.
17, 20, 22
 Nevertheless, the benefit of a large sample size was 
diminished by the fact the data set had large amounts of missing data and that the study 
population did not include subjects who lacked insurance or who were on public insurance.  
The cross-sectional designs were much more varied in their quality; one was good quality,
28
 
four were fair quality,
23-24, 26, 30
 and three were poor quality.
25, 27, 29
 Although poor quality studies 
were included in this review due to the paucity of literature on the subject, their results need to 
be cautiously interpreted given how fraught they are with flaws. For example, the study by Patel 
was only a published abstract with no corresponding full manuscript in publication, which gives 
the audience no idea about its quality or its methods.
27
 Another study assessed vaccination rates 
in clinics where the vaccine was unavailable for parts of the study period, which has the potential 
to greatly affect the outcome in question.
25
 The rest of the cross-sectional studies were mainly 
limited by the lack of response from survey participants, which might lead to a response bias.  
Table 4. Evaluation of Each Study’s Quality 
 
Author Title Generalizability Conclusion 
Overall 
Quality 
Chao, et al (1) 
Correlates for 
completion of 3-
Fairly good, but all 
patients were within the 
HPV vaccination 
completion rates are 
Fair 
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dose regimen of 
HPV vaccine in 
female members of 
a managed care 
organization 
insurance system. No 
public insurance people 
low 
Chao, et al (2) 
Correlates for 
Human 
Papillomavirus 
Vaccination of 
Adolescent Girls and 
Young Women in a 
Managed Care 
Organization 
Fairly good, but all 
patients were within the 
insurance system. No 
public insurance people 
HPV vaccination 
initiation is negatively 
associated with black 
race, low income, and 
other factors. 
Adolescents are more 
likely to initiate than 
young girls or young 
women 
Fair 
Chao, et al (3) 
Papanicolaou 
Screening Behavior 
in Mothers and 
Human 
Papillomavirus 
Vaccine Uptake in 
Adolescent Girls 
Good - wide patient 
population, even with 
many exclusions.  
Daughters who 
received HPV vaccine 
were 50% more likely 
to have a mom with a 
pap test in the past 3 
years. Vaccine 
completion was only 
41% within 1 year, but 
most were on time.  
Fair 
Conroy, et al 
Human 
Papillomavirus 
Vaccine Uptake, 
Predictors of 
Vaccination, and 
Self-Reported 
Barriers to 
Vaccination 
Poor - small sample, 
from an urban, hospital-
based adolescent 
primary care clinic.  
HPV vaccination rates 
were low (36%), and 
completion was even 
lower (13%). Factors 
associated with 
vaccination included 
insurance and 
normative beliefs.  
Fair 
Dempsey, et al (1) 
Patient and Clinic 
Factors associated 
with adolescent 
human 
papillomavirus 
vaccine utilization 
within a university-
based health system 
Poor - university setting, 
and no women over age 
18.  
HPV vaccination 
initiation is associated 
with African American 
Race and public 
insurance. Completion 
is associated with 
White race and 
Private insurance. 
Completion rates are 
low.  
Good 
Dempsey, et al (2) 
Parents' Views of 3 
Shot-Related Visits: 
Implications for Use 
of Adolescent 
Vaccines Like 
Human 
Fair - response bias 
Among national 
sample of parents of 
adolescents, high 
willingness to 
participate in 3-dose 
vaccination visits, but 
Fair 
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Papillomavirus 
Vaccine 
many barriers 
included lack of 
perceived need for 
frequent visits.  
Jain, et al 
Human 
papillomavirus 
(HPV) awareness 
and vaccination 
initiation among 
women in the 
United States, 
National 
Immunization 
Survey - Adult 2007 
Poor - not the right age 
group 
Vaccination initiation 
was 10% among 
women 18-26 years 
old, and initiation is 
associated with not 
being married, having 
insurance.  
Fair 
Kahn, et al 
Rates of Human 
Papillomavirus 
Vaccination, 
Attitudes about 
Vaccination, and 
Human 
Papillomavirus 
Prevalence in Young 
Women 
Poor - no vaccine 
availability 
Vaccine initiation was 
only 5%. Completion 
was only 0.2%.  
Poor 
Licht, et al 
Is use of the HPV 
vaccine among 
female college 
students related to 
HPV knowledge and 
risk perception?  
Fair - college students 
seem to be quite varied.  
Vaccine initiation was 
43.6%. Completion 
was 53% among those 
who did start. 
Younger age and 
White race associated 
with vaccination.  
Fair 
Neubrand, et al 
Factors Associated 
with Completion of 
the Human 
Papillomavirus 
Vaccine Series 
Fair - small sample, only 
1 academic center 
sampled.  
Completion rate is 
58.2%. Race (Hispanic) 
associated with less 
completion in 
multivariate logistic 
model.  
Fair 
Patel, et al.  
Are Our Adolescent 
Females Becoming 
"One Less"? HPV 
Vaccination Rates 
and Barriers to 
Vaccination 
Poor - no idea about 
quality of the study 
Vaccination for HPV is 
lower than tetanus 
vaccination in an 
urban practice setting.  
Poor 
Reiter, et al 
How much will it 
hurt? HPV vaccine 
side effects and 
influence on 
completion of the 
Fair - patients were 
oversampled for 10-18 
year old daughters, 
African American race, 
and rural.  
Pain is not related to 
vaccine uptake.  
Good 
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three-dose regimen 
Rosenthal, et al 
Predictors of HPV 
vaccine uptake 
among women aged 
19-26: Importance 
of a physician's 
recommendation 
Poor - poor response 
rate, sampling bias  
Physician 
recommendation and 
discussion is vital for 
vaccine initiation 
among 19-26 year 
olds. 
Poor 
Stokley, et al 
National, State, and 
Local Area 
Vaccination 
Coverage Among 
Adolescents Aged 
13 - 17 Years -- 
United States, 2008 
Fair - large national 
sample, but because of 
telephone survey and 
loss of respondents 
(only 58.7% response 
rate), it's hard to 
generalize 
37.2% initiation rate, 
17.9% completion 
rate. 
Fair 
 
Discussion 
Summary of Evidence: 
Overall, the evidence is too heterogeneous for the data to be combined in a meta-analysis. 
Nevertheless, the studies themselves point to a HPV vaccine initiation rate between 25-45%, 
depending on the specific patient population (11-12 year olds or 18-26 year olds for example). 
This number is likely to increase over time as the vaccine becomes more established within the 
medical system and becomes more accepted as a safe and efficacious option against cervical 
cancer. The vaccine completion rates also varied greatly, but most studies indicated a completion 
rate (sampling only from a group that initiated) between 40-50%. The overall completion rate, 
which refers to the number of females who completed the vaccine series out of the entire group 
of eligible subjects (not just the ones who initiated), ranged between 15-18% in two studies.
19, 30
 
When discussing correlates for vaccine initiation or series completion, many studies 
employed varied statistical methods to find significant predictors, such as a log-log binomial 
regression model, logistic regression, or simple bivariate analyses. Given the different methods, 
the outputs were different as well; some studies used risk ratios, others used odds ratios, and 
some used percentages. While it is difficult to compare the numbers, the conclusions were 
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similar across all studies. Vaccine initiation and completion are associated with covariates like 
age, race, ethnicity, insurance type and status, socioeconomic status, normative beliefs about the 
vaccine, a mother’s pap smear history, and discussion with a physician. Some studies found that 
economically disadvantaged females or minorities like Hispanics or African Americans had 
paradoxically higher rates of vaccine initiation, but that may be due to the fact that economically 
disadvantaged patients have access to the Vaccines for Children program and do not have to face 
the financial barrier of paying for the vaccine that some privately insured patients face. The 
majority of African-Americans and Hispanics in some of these studies were also below the 
poverty level – which might indicate that the higher vaccination initiation rates might be due to 
socioeconomic factors rather than racial factors.
19, 30
 When looking at completion rates, however, 
private insurance and White race become predictors for completion, which then indicates that 
there might be some differences between getting a patient to initiate the vaccine and having them 
return for the 2
nd
 and 3
rd
 visit to complete the series. 
It is quite difficult for a clinician to apply the literature known about HPV vaccine to his or 
her patient population since each study has a specific target patient population (limited by age 
range, practice location, and insurance status), and has limitations that impair its generalizability 
(poor study design, lack of adequate follow-up, or even lack of vaccine availability during the 
study period). Furthermore, with the exception of the MMWR report utilizing 2008 data, most of 
the studies cite data collected either in 2006 or 2007. Hopefully this report has synthesized the 
data available so that a clinician may apply the current knowledge about vaccination rates to his 
or her own patient population. 
Thus, a study with a larger, representative sample of patients with enough follow-up periods 
to adequately capture enough data for completion rates and factors associated with those is 
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needed. While three of the studies also looked at on-time dosing rates, they were not explicitly 
discussed and had no correlates for on-time dosing either.  
Limitations:  
At the outcome level, the main limitation of trying to compare each of the studies is that the 
patient population and follow-up periods are not the same across studies. Various studies had 
shorter follow-up times which would decrease completion rates, and furthermore, the different 
patient populations studied might also lead to systematic differences in vaccination rates and 
correlates for uptake or completion. This makes it hard to make generalizable statements when 
pooling the outcomes. Furthermore, some studies measured completion rates of the HPV vaccine 
relative to the entire study population while other studies measured completion rates within a 
cohort of patients that initiated the vaccine. Therefore, it is difficult to compare completion 
percentages without knowing the absolute numbers, and some studies did not provide the number 
of patients that initiated the vaccine.  
At the study level, many of the studies had limitations due to small sample size, missing data, 
or weak study design. A lot of the studies were cross-sectional surveys, which subjects the 
results to recall bias and non-response bias. Furthermore, although a cross-sectional survey 
design is good for detecting prevalence of a condition (such as vaccine uptake), it cannot 
appropriately address vaccination completion rates, given that completion of the series is time-
dependent; some females who would complete the series might not be captured with a survey at 
that moment in time. The cohort studies (retrospective or prospective) were limited by missing 
data (2 studies), a small sample size (2 studies), and limited generalizability due to a selective 
patient population (4 studies). Many studies also used logistic regression models to find 
significant predictors of vaccine initiation or completion. Very few of these studies, however, 
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reported about the sample sizes used in the models, and what impact missing data had on the 
study results.  
Conclusions:  
The quadrivalent HPV vaccine has only been available for a short period of time (less than 4 
years). There have been no systematic reviews attempting to document the national rate of 
vaccine initiation or completion. When discussing HPV vaccine initiation and completion rates, 
one of the most widely quoted studies is the CDC report about vaccination coverage among 
adolescents aged 13-17 years in the US.
30
 This phenomenon may be due to its governmental 
affiliation, national sample, and recent publication, but the study is limited by its methods 
(telephone survey) and its low response rate (58.7%). Furthermore, they did not have enough 
data to make conclusions about 2007 completion rates. Nevertheless, initiation rates around 37% 
and completion rates of 17.9% (but 41.8% of those that initiated) in 2008 have been cited by 
many studies as truly representative of the national rate.  
Thus an implication for future research would be to update the literature using more current 
data about the HPV vaccination rates. A study with a longer follow-up period could also increase 
the robustness of the results and the use of a more inclusive study population (i.e. using 9-26 
year olds instead of 13-17 year olds) would yield more generalizable results as well. Lastly, a 
study investigating the rates of on-time dosing would be helpful given the paucity of data on the 
subject. Given the fact that there is no evidence regarding the efficacy of the HPV vaccine with a 
delayed dosing schedule or an incomplete dosing regimen, knowing the prevalence of both 
problems might be informative for development of interventions to boost vaccination rates if 
future studies do show a decrease in efficacy given poor adherence to the recommended dosing 
schedule or incomplete vaccination.  
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Introduction: 
 
The human papillomavirus (HPV) infects an estimated 6.2 million people in the United 
States every year, making it the most commonly sexually transmitted infection (STI).
1
 Persistent 
infection with high-risk HPV serotypes, including types 16 and 18, is the most important risk 
factor for developing cervical cancer
1
 while infection with  HPV types 6 and 11 is responsible 
for most anogenital wart cases.
1
 The quadrivalent HPV vaccine (HPV4, Gardasil) is designed to 
prevent cervical cancer and anogenital warts by preventing infection with HPV types 6, 11, 16, 
and 18.
2
 Since HPV is a widespread STI, the HPV vaccine is most effective when administered 
prior to sexual debut.
3
 Therefore, the Advisory Committee on Immunization Practices (ACIP) 
recommends routine vaccination of girls starting at 11-12 years of age with catch-up vaccination 
of vaccine naïve young women suggested up through 26 years of age.
1
 The HPV4 vaccine is 
administered as a 3 dose series with the 2
nd
 and 3
rd
 dose given at 2 and 6 months following the 
first dose, respectively. 
Despite the ACIP’s recommendation and the government’s support in making HPV4 vaccine 
series available through the Vaccines For Children (VFC) Program,
4
 the reported rates of HPV 
vaccination remain low. Nationally, only 37.2% of adolescent females (aged 13-17) had initiated 
the HPV vaccine series in 2008, and only 17.9% of the adolescent females had received all 3 
doses.
8
 Furthermore, adherence to the recommended dosing intervals is likely to be poor among 
adolescents.
10-12
 
A few studies have examined correlates for completion of the HPV vaccination series.
17-19
 
However, we are not aware of any studies documenting factors associated with on-time dosing in 
addition to vaccine series completion. Therefore, the goal of this study was to measure the rates 
of HPV vaccine series completion and on-time dosing based on the recommended schedule 
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among those who initiate the series, along with factors associated with series completion and on-
time dosing.  This information may be helpful in developing strategies to increase on-time 
completion of HPV vaccination among adolescent girls.  
Methods:  
Study Design 
This retrospective cohort study was a secondary data analysis of computerized immunization 
records in the state of North Carolina. The study protocol was submitted to the Duke University 
Health System Institutional Review Board (IRB) and exempted from full review. 
Data Source 
The North Carolina Immunization Registry (NCIR) is a statewide database containing 
information on immunizations delivered in all the health departments and more than 600 private 
practices throughout the state. As of 2009, 72% of public providers and 61% of private providers 
used the registry to record immunizations. A public provider is defined as a public health 
department, a community/migrant health/rural health clinic, Indian health service clinic, or any 
public clinic that provides immunizations, such as a publically funded non-profit neighborhood 
clinic. A private provider is defined as a private health plan, group of doctors, or clinic that is not 
a federally qualified health center (FQHC). For each individual included in the dataset there are 
fields for the person’s county of residence, race, ethnicity, and each vaccination date. For every 
individual vaccination date the recipient’s age, clinic type, and funding source for the vaccine 
could also be entered. 
Study Population 
Our study sample consisted of all females whose immunization information was included in 
the NCIR and who received at least one dose of the HPV vaccine series of which the first dose 
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was administered between 9 and 26 years of age. Entries were excluded if the date of the first 
dose entered was before 6/8/2006 (the day the FDA approved the HPV4 vaccine) or after 
2/17/2009 (to allow time for all those in the study to potentially complete the series on-time 
before the date of data censoring). For these reasons, of the 172,948 girls and young women in 
the data set, 34,118 were excluded (273 were less than 9 years of age, 185 were greater than 26 
years of age, 286 entries had a first dose before 6/8/2006, and 33,374 entries had a first dose after 
2/17/2009). Seven entries with obviously discordant dates, such as duplications or vaccinations 
only days apart, were also excluded from analysis. Our final sample consisted of 138,823 girls 
and young women. 
Variables 
The main outcomes were completion of the HPV vaccine series and on-time completion of 
the vaccine series. Completion of the series was defined as documentation of at least 3 separate 
HPV vaccine doses. On-time completion was assessed by the intervals between the three doses. 
An on-time dose was defined as 2 ± 1 months (28-84 days) between the first two doses and 6 ± 2 
months (112-224 days) between the first and third doses as outlined by the HPV4 package 
insert.
13
 This dosing window was used since studies by Merck have shown no reduction in 
immunogenicity with the aforementioned schedule flexibility.
13
  
The exposure variables examined were: race, ethnicity, age, county of residence, the clinic 
type, and funding type. Race was categorized as American Indian/Alaska Native, Asian, 
Black/African-American, Native Hawaiian/Pacific Islander, Other, or White. Ethnicity was 
divided into Hispanic or non-Hispanic. Clinic type (Family, local health department, hospital, 
internal medicine, juvenile corrections, K-12 school, university/college, pediatrician, or other), 
source of funding (public or private), and age (in months) of the recipient were listed for each 
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vaccine dose. Each variable was not self-reported, but rather manually entered for each entry by 
the provider using the registry. 
Data Analysis  
We used means or proportions to describe the characteristics of the girls and young women 
in the sample. We examined factors associated with series completion as well as on-time dosing 
using unadjusted bivariate analyses and tested for significance using Pearson’s chi-squared test. 
We used logistic regression to examine the independent effects of the exposure variables on 
series completion and on-time dosing. The subjects were categorized into three age groups, 9-12 
years of age (young girls), 13-17 years of age (adolescents), and 18-26 years of age (young 
women), in order to compare the differences among age groups with regards to vaccination 
completion and on-time dosing. Counties were classified as metropolitan statistical areas based 
on US census data.
31
 For the logistic regression analysis, age, funding source and clinic type 
were based on the first dose of the vaccine. We used listwise deletion to handle missing data. 
This method of logistic regression ignores all entries with missing data and only uses entries with 
a complete set of variables in the analysis, which yields a complete-case analysis. To examine 
the effect of missing data, we created a regression model with dummy variables for all unknowns 
and compared it to the complete-case analysis. All p-values were considered significant at ≤ 0.05 
and 95% confidence intervals were reported when appropriate. Stata Version 11.0 (Statacorp, 
College Station, TX) was used for all analyses. 
Results  
Characteristics of the Study Population 
The girls and young women in the cohort were mainly White (63%) and non-Hispanic (91%) 
(Table 1). They lived mostly in metropolitan statistical areas (70%), and about half had private 
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insurance. The median age was 14.8 years, 15.1 years, and 15.3 years at doses 1, 2, and 3 
respectively. The average length of follow-up was 19 months, with a range of 8 months to 40 
months.   
Completion Rates and On-Time Dosing 
Of the 138,823 girls and young women in the study population, 23% (n = 31,771) received a 
single dose of the quadrivalent HPV vaccine; 22% (n = 30,561) received only two doses; 55% (n 
= 76,491) completed the HPV vaccine series. Approximately 28% of the entire group (n = 
39,123), completed the HPV vaccine series on-time (Figure 1). For those who received a dose 
that was not on-time, the median interval in relation to the first dose was 5.7 months for the 
second dose and 10.8 months for the third dose. Most of the girls and young women (82%) who 
completed the series did so within 12 months, and nearly all (98%) had completed the series by 
24 months. Over 83% of those (3,354/4,013) who initiated the vaccine series in 2006 completed 
it by the final study date, compared to 32% (1,585/4,985) of those who initiated the vaccine in 
2009. The percentage of girls and young women who have completed the series on-time out of 
those who initiated the series has decreased each year, from 43.2% (1,732/4,013) in 2006 to 
25.2% (1,258/4,985) in 2009 (Figure 2). Among those who received the second dose on time, 
72.8% received the third dose on time, whereas only 19.6% of females received the third dose on 
time if they were late in receiving the second dose (p-value < 0.001).   
Factors Associated with Vaccine Completion and On Time Vaccine Dosing   
Vaccine series completion and on-time series completion varied significantly with race 
(p<0.001 for both) with Whites more likely than Blacks to complete the series (59% vs. 43%) as 
well as complete the series on-time (55% vs. 43%). Non-Hispanics were also more likely than 
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Hispanics to both complete the series (54% vs. 46%, p<0.001) and do so on-time (51% vs. 47%, 
p<0.001).  
Both those 9-12 years of age and 13-17 years of age had similar completion rates (57%) that 
were higher than those 18-26 years of age (42%). Nevertheless, when comparing on-time dosing 
rates, of those 18-26 years of age who completed the series 55% did so on-time, compared with 
approximately 50% of those 9-12 years of age and 51% of those 13-17 years of age.  Compared 
to those whose vaccine was publically funded, the girls and young women whose vaccine was 
funded by private insurance were more likely to complete the series (61% vs. 46%, p<0.001 and 
do so on-time (54% vs., 47%, p<0.001)    
Completion and on-time dosing rates differed by the type of health care clinic from which the 
girls and young women received immunizations. Those vaccinated at pediatric clinics had the 
highest completion rates at 61%, followed by those vaccinated at family medicine practices at 
53% and those vaccinated at local health departments at 39%. For on-time dosing, girls and 
young women vaccinated at family medicine practices had the highest rate at 56%, while those 
vaccinated at pediatric clinics or at local health departments had on-time dosing rates at 50%.   
Of those who completed the series (n = 76,491), the vast majority (96.1%) stayed with the 
same clinic, and 52% of them completed the series on-time. Only 28% of those who switched 
clinic type, however, completed the series on-time. Additionally, 85% (47,802 / 56,389) of 
females who completed the series stayed with the same funding source, and 52% of them 
completed the series on-time. Among those who switched funding sources, 47% completed the 
series on time.  
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Independent Associations with Vaccine Completion 
Compared to Whites, African-Americans were less likely to complete the series (OR 0.55; 
95% CI 0.53 – 0.56) as well as complete it on-time (OR 0.66; 95% CI 0.64 – 0.69) (Table 3). 
American Indians were also less likely to complete the series (OR 0.68; 95% CI 0.61 – 0.77) and 
do so on-time (OR 0.58; 95% CI 0.49 – 0.69) than Whites. Hispanics were less likely to 
complete the series (OR 0.75; 95% CI 0.72 – 0.79) and do so on-time than non-Hispanics (OR 
0.84; 95% CI 0.79 – 0.90). Young women were less likely to complete the series than the 
adolescents (OR 0.54; 95% CI 0.52 – 0.56), but were more likely to finish the series on-time (OR 
1.08; 95% CI 1.03 – 1.14) if completed. Those who lived outside a metropolitan statistical area 
were also more likely both to complete the series and do so on-time. Those whose clinic type 
was a family medicine practice or local health department were less likely to complete the series 
than those whose clinic was a pediatric practice. Patients who went to family medicine practices, 
however, were more likely to complete the series on-time than patients of pediatric clinics. The 
females who saw providers in K-12 schools, however, were much more likely to both complete 
the series and do so on-time than those who went to pediatric clinics (OR 2.40; 95% CI 1.82 – 
3.17 and OR 1.77; 95% CI 1.30 – 2.39, respectively). Public funding for vaccines was associated 
with lower completion rates (OR: 0.69, 0.68 – 0.71) and on-time dosing rates (OR: 0.80, 0.77 – 
0.83) when compared with private funding.  
The results for the logistic regression model using a complete-case analysis are similar to the 
model with dummy variables for unknown data, except that local health departments and 
Hispanic ethnicity became statistically insignificant for on-time dosing. For series completion, 
age (9-12 years) also became insignificant.  
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Discussion 
Using a large statewide database, we found that after three years of availability on the 
market, completion of the HPV vaccine series among those who initiate it is low (overall 55%), 
and on-time dosing of the vaccine is even lower (overall 28%). When examining completion 
rates stratified by the year the patient initiated the vaccine, the percentage of those completing 
the series increased steadily over time (32% after one year to 84% after three years). Most of the 
girls and young women completing the vaccination series, however, did so within one year 
(82%). The percentage of those completing the series on-time, however, has decreased from 43% 
of those who initiated the series in 2006 to 25% for those who initiated in 2009. This likely 
means a sizeable majority of those who started the series will complete it, but not on-time.  
African Americans and Hispanics were less likely to complete the series and receive all doses 
on-time compared to Whites and non-Hispanics. Furthermore, private funding for the vaccine 
was associated with higher odds of completion and on-time dosing compared to public funding. 
These results are in agreement with previous studies about HPV vaccination completion, which 
also found that African Americans and those on public health insurance were less likely than 
those of other races or those with private health insurance to complete the series.
17-19, 30
 Studies 
examining factors associated with reduced vaccine series completion have shown mixed 
results
19, 30
.
20, 26
 Differences may be secondary to the vast differences in study population 
demographics. Nevertheless, the results from our study indicate that the rates of completion of 
the series as well as on-time dosing of the three doses differ across racial and socioeconomic 
groups, a finding that is consistent with the few existing studies investigating correlates for 
completion (and not initiation).More work is needed to develop and test interventions or 
programs that aim to eliminate disparities in vaccination rates.  
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We found the factors associated with series completion and on-time dosing to be similar but 
not identical. For example, our data suggest that young women (18-26 year olds) are much less 
likely to complete the series than the adolescents(13-17 year olds), but of those who do, are more 
likely to complete it on-time. Our results are in agreement with other studies that have shown 
that college-age women are much less likely to initiate the vaccine than younger girls.
20-21, 26
 This 
finding might be due to the fact that young adult women are not covered under the Vaccine for 
Children Program, or they might have lost insurance previously provided by their parent’s 
private coverage. Nevertheless, the observation that of those who do complete the series, those in 
the adult age range are more likely to complete it on-time may be due to their ability to have a 
more flexible schedule than younger girls. Furthermore, compared to younger women, older 
women may exhibit more health care seeking activities and hence have more opportunities for 
HPV vaccination. One such example is the pap test, which has been shown in one study to be a 
predictor of HPV vaccination amongst daughters of mothers with a history of regular pap 
smears.
22
 Our result, however, is in contrast to one other study by Chao, et al., which found that 
those aged 18-26 years old had higher vaccination completion rates than younger girls aged 9-17 
year old (47.1% versus 41.9%).
17
 This latter study was limited by a fairly small sample in the 
older age group and only looked at women within a managed care organization which eliminates 
observed differences in insurance coverage between older women and younger girls as a 
potential barrier to vaccination completion.  
With regards to clinic type, patients of who saw providers at pediatric clinics were more 
likely than those of at family medicine practices and local health departments to complete the 
series. This finding is in contrast to that in a study by Chao, et al., which stated that patients of 
pediatricians had lower completion rates than patients of family medicine or internal medicine 
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physicians.
17
 The study populations between our study and the study by Chao, et al., are very 
different, but the reason for the contrasting results between studies is unclear. Patients 
immunized by providers at K-12 schools were much more likely to complete the series and 
complete the series on-time than those seen at pediatric clinics, but the results need to be 
tempered by the fact that this subgroup had a relatively small sample size (n = 244). Larger 
samples need to be gathered before these results can be assuredly generalized to the external 
source population, but these results are in agreement with other studies that have shown that 
school-based vaccination programs are effective at series completion.
32
 Studies have shown that 
physician recommendations are very important in determining vaccine uptake,
29, 33
 and thus any 
differences in clinic type vaccination rates may be due to the differences in acceptability of the 
vaccine amongst providers.
34-35
  If that is the case, interventions targeted at improving provider 
acceptance of the vaccine as well as improving provider recommendation of the vaccine to the 
target population (ideally females 11-12 years of age) would increase vaccination rates.
36
  
Living in a rural area (non-Metropolitan Statistical Area) was statistically significantly 
associated with increased completion and on-time dosing rates, but the clinical importance of 
such a result is not compelling. This is in agreement with other studies which found that distance 
from a clinic was not associated with differences in completion rates.
18
 The differences among 
county vaccination rates are probably due to differences in area poverty and socioeconomic 
status rather than rurality, as shown by one study looking at HPV vaccination rates and 
geographic disparities.
37
  
Strengths and Limitations 
One of the strengths of the study is the data source: the North Carolina Immunization 
Registry (NCIR), based on the Wisconsin Immunization registry, is a well-validated and robust 
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Immunization Information System that satisfies the 12 minimum functional standards developed 
by the CDC.
38
 The most current numbers suggest that the NCIR has strong penetrance among the 
providers in the state; as of 2009, 61% of private providers and 72% of public providers 
(including all local health departments) were using the registry to record immunization records 
(personal correspondence, 2010). It is also a large repository of data; 138,823 separate patients 
were used for analysis, which makes the results very robust. Furthermore, the patient sample is 
diverse, which allows for more generalizable results. Nevertheless, the registry is only robust if 
the data entry is complete. Inconsistencies in how each practice records its immunizations, 
systematic differences between practices inside the registry from those outside the registry, and 
the migration of people in and out of the system will make it more difficult to generalize the 
results from this study. 
The biggest limitation to this study was the large proportion of entries with some missing 
data. Many entries were missing data about race, ethnicity, funding source, and county of 
residence. This limited the number of females available for analysis using the regression model, 
but the logistic model utilizing dummy variables for unknown values did not change the results 
drastically, which is reassuring to the validity of the results, even with missing data. Multiple 
imputation was considered as a method to evaluate the effect of missing data on the outcomes. 
However, the dataset had limited variables from which we could draw upon for imputation of all 
the missing data. Also, we were uncomfortable with the assumption that variables were missing 
at random, and were not willing to impute race (and other missing variables) based on the 
outcome, which we would then use to make conclusions about the associations between these 
exposures and the outcome. Thus we decided to compare the complete-case analysis and a model 
using all entries with dummy variables for unknown values. 
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Conclusions and Implications 
Among girls and young women who initiate the HPV vaccination series, overall completion 
rates are low, but given enough time (three years), most of those who begin the series will 
complete it.  On-time dosing rates, however, are declining, and have been hovering at 25% for 
the past two years. The significance of delayed dosing with respect to vaccine immunogenicity 
and vaccine effectiveness are not well defined.  
Additional studies are currently underway to assess how the late timing of the intervals 
between the doses affects the humoral immune response.
13-16
 The factors associated with 
completion and on-time dosing are similar. African-American race, Hispanic ethnicity, and 
having public insurance are associated with reduced series completion and on-time dosing. 
Efforts are needed to eliminate disparities in HPV vaccine delivery. Finally, if future research 
shows that delayed dosing leads to reduced vaccine immunogenicity, then new vaccines with 
reduced dosing requirements or strategies designed to improve on-time vaccine delivery will be 
needed. 
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Table 1. Characteristics of Girls and Young Women  in Study Sample (n = 138,823) 
 
 Percentage 
Race (n = 113,309)  
American Indian / Alaskan Native 1.2% 
Asian 1.3% 
Black 33.1% 
Native Hawaiian / Pacific Islander 0.1% 
Other 1.4% 
White 62.9% 
  
Ethnicity (n = 96,110)  
Hispanic 9.0% 
Non-Hispanic 91.0% 
  
Age at First Dose (n = 138,823)  
9-12 years old 28.2% 
13-17 years old 57.1% 
18-26 years old 14.7% 
  
County (n = 136,497)  
Metropolitan Statistical Area 70.5% 
Non-MSA 29.5% 
  
Clinic Type (n = 138,823)  
Family Provider 23.5% 
Local Health Department 18.8% 
Pediatric Provider 56.5% 
Hospital 0.3% 
Internal Medicine Provider 0.2% 
Juvenile Corrections 0.1% 
School K-12 0.2% 
University/College 0.3% 
Other 0.1% 
  
Funding Type (n = 110,783)  
Private 51.2% 
Public 48.8% 
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Table 2. Associations with HPV Vaccination Series Completion and On-Time Completion 
 
Characteristic 
 
Total 
Number 
% Completed 
Series 
Total 
Number 
% All 3 
doses on 
time 
Race (n = 113,309)     
American Indian / Alaskan Native 1,325 47.2% 625 41.0% 
Asian 1,486 56.0% 832 50.6% 
Black 37,490 43.4% 16,275 43.1% 
Native Hawaiian / Pacific Islander 136 50.7% 69 53.6% 
Other 1,616 56.0% 905 47.5% 
White 71,256 59.0% 42,037 54.5% 
     
Ethnicity (n = 96,110)     
Hispanic 8,633 46.3% 3,995 47.0% 
Non-Hispanic 87,477 53.5% 46,801 50.9% 
     
County (n = 136,497)     
Metropolitan Statistical Area 96,188 55.3% 53,233 49.8% 
Non-MSA 40,309 54.2% 21,838 54.2% 
     
Clinic Type (n = 138,823)     
Family Provider 32,652 52.9% 17,258 56.2% 
Local Health Department 26,154 39.4% 10,314 49.6% 
Pediatric Provider 78,425 61.3% 48,081 49.8% 
Hospital 435 41.2% 179 39.1% 
Internal Medicine Provider 234 53.9% 126 37.3% 
Juvenile Corrections 92 54.4% 50 56.0% 
School K-12 244 70.5% 172 54.7% 
University/College 434 51.4% 223 50.2% 
Other 153 57.5% 88 37.5% 
     
Funding Type (n = 110,783)     
Private 56,711 61.2% 34,686 53.6% 
Public 54,072 45.6% 24,652 47.3% 
     
Age at First Dose (n = 138,823)     
9-12 years old 39,166 57.5% 22,515 50.0% 
13-17 years old 79,325 57.4% 45,492 51.0% 
18-26 years old 20,332 41.7% 8,484 55.1% 
* Note: All Pearson’s Chi-Squared values were < 0.001.  
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Table 3. Adjusted Associations with HPV Vaccination Series Completion and On-Time 
Completion 
 
Adjusted for Race, Ethnicity, County Status, Clinic Type, Funding Source, and Age of first dose  
 OR for Series 
Completion 
(n = 138,823) 
95% 
Confidence 
Interval 
OR for 
On-Time 
Dosing 
(n = 76,491) 
95% 
Confidence 
Interval 
Race (White as Referent)     
American Indian or Alaska Native 0.68 0.61 – 0.77 0.58 0.49 – 0.69 
Asian 1.04 0.94 – 1.16 0.99 0.85 – 1.14 
Black or African-American 0.55 0.53 – 0.56 0.66 0.64 – 0.69 
Native Hawaiian or Pacific Islander 0.78 0.56 – 1.11 1.10 0.68 – 1.78 
Other 1.12 1.01– 1.25 0.88 0.77– 1.01 
Unknown 0.94 0.90 – 0.97 0.90 0.86 – 0.94 
     
Ethnicity (non-Hispanic as 
Referent) 
    
Hispanic  0.75 0.72 – 0.79 0.84 0.79 – 0.90 
Unknown 0.97 0.94 – 0.99 1.01 0.97 – 1.05 
     
County Status (MSA as Referent)     
Non-MSA 1.04 1.01 – 1.07 1.23 1.19 – 1.27 
Unknown 0.97 0.89 – 1.06 1.07 0.96 – 1.19 
     
Clinic Type (Pediatrician as 
Referent) 
    
Family Provider 0. 78 0.76 – 0.80 1.34 1.29 – 1.39 
Local Health Department 0.48 0.47 – 0.50 1.08 1.03 – 1.13 
Hospital 0.49 0.40 – 0.59 0.82 0.61 – 1.12 
Internal Medicine 0.75 0.57 – 0.98 0.69 0.47 – 1.00 
Juvenile Corrections 0.86 0.57 – 1.31 1.71 0.97 – 2.99 
K-12 School 2.40 1.82 – 3.17 1.77 1.30 – 2.39 
University/College 0.72 0.59 – 0.87 0.93 0.71 – 1.21 
Other 1.24 0.89 – 1.75 0.82 0.52 – 1.30 
     
Funding Source (Private as the 
Referent) 
    
Public Funding 0.69 0.68 – 0.71 0.80 0.77 – 0.83 
Unknown 1.23 1.20 – 1.27 0.90 0.87 – 0.94 
     
Age (13-17 as Referent)     
Age 9-12 0.97 0.95 – 1.00 0.99 0.95 – 1.02 
Age 18-26 0.54 0.52 – 0.56 1.08 1.03 – 1.14 
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Figure 1. The pie graph on the left indicates the proportions of females aged 9-26 years of age 
receiving differing numbers of doses of HPV vaccine. The pie chart on the right displays the 
proportions of females who completed the series that received all three doses on-time or not on-
time.  
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Figure 2. The percentage of females who completed the HPV vaccine series on-time stratified by 
the year the HPV vaccine series was initiated. The number of females who initiated the series in 
each year is shown above the year indicated. 
 
 
 
 
 
 
 
